Back to top

Top Ranked Growth Stocks to Buy for January 8th

Read MoreHide Full Article

Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, January 8th:

S&P Global Inc. (SPGI - Free Report) : This provider of independent ratings, benchmarks and data, which carries a Zacks Rank #2 (Buy), has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.3% over the last 60 days.

S&P Global Inc. Price and Consensus

S&P Global Inc. Price and Consensus | S&P Global Inc. Quote

S&P Global has a PEG ratio 1.94, compared with 2.16 for the industry. The company possesses a Growth Score of A.

Cigna Corporation (CI - Free Report) : This health services organization, which carries a Zacks Rank #1 (Strong Buy), has witnessed the Zacks Consensus Estimate for its current year earnings rising 0.3% over the last 60 days.

Cigna has a PEG ratio 1.44, compared with 2.83 for the industry. The company possesses a Growth Score of A.

Copart, Inc. (CPRT - Free Report) : This vehicle remarketing services provider, which carries a Zacks Rank #1 (Strong Buy), has witnessed the Zacks Consensus Estimate for its current year earnings increasing 7.8% over the last 60 days.

Copart, Inc. Price and Consensus

Copart, Inc. Price and Consensus | Copart, Inc. Quote

Copart has a PEG ratio 1.42, compared with 1.84 for the industry. The company possesses a Growth Score of A.

Lam Research Corporation (LRCX - Free Report) : This semiconductor processing equipment manufacturer, which carries a Zacks Rank #2 (Buy), has witnessed the Zacks Consensus Estimate for its current year earnings rising 0.1% over the last 60 days.

Lam Research has a PEG ratio 0.90, compared with 1.24 for the industry. The company possesses a Growth Score of A.

See the full list of top ranked stocks here                         

Learn more about the Growth score and how it is calculated here.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


S&P Global Inc. (SPGI) - free report >>

Lam Research Corporation (LRCX) - free report >>

Copart, Inc. (CPRT) - free report >>

Cigna Corporation (CI) - free report >>

More from Zacks Zacks #1 Rank Additions

You May Like